163 related articles for article (PubMed ID: 32034028)
1. Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Kameda R; Nomoto H; Cho KY; Kawata S; Omori K; Takeuchi J; Nagai S; Kurihara Y; Aoki S; Nakamura A; Atsumi T; Miyoshi H
BMJ Open; 2020 Feb; 10(2):e034883. PubMed ID: 32034028
[TBL] [Abstract][Full Text] [Related]
2. Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
Nomoto H; Furusawa S; Nakamura A; Takeuchi J; Nagai S; Yokoyama H; Sakuma I; Taneda S; Kurihara Y; Aoki S; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
BMJ Open; 2022 May; 12(5):e056885. PubMed ID: 35584872
[TBL] [Abstract][Full Text] [Related]
3. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
Hashimoto-Kameda R; Cho KY; Nomoto H; Nakamura A; Omori K; Nagai S; Edagawa S; Kawata S; Takeuchi J; Kameda H; Kurihara Y; Aoki S; Atsumi T; Miyoshi H;
Diabetes Res Clin Pract; 2021 Oct; 180():109069. PubMed ID: 34563585
[TBL] [Abstract][Full Text] [Related]
4. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
5. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1245-55. PubMed ID: 24708292
[TBL] [Abstract][Full Text] [Related]
8. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
[TBL] [Abstract][Full Text] [Related]
9. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.
Seino Y; Sasaki T; Fukatsu A; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1219-30. PubMed ID: 24597840
[TBL] [Abstract][Full Text] [Related]
11. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
Ejiri K; Miyoshi T; Nakamura K; Sakuragi S; Munemasa M; Namba S; Takaishi A; Ito H
BMJ Open; 2019 Mar; 9(3):e026590. PubMed ID: 30928954
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
Seino Y; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Curr Med Res Opin; 2014 Jul; 30(7):1231-44. PubMed ID: 24673496
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
15. The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT).
Haraguchi A; Shigeno R; Horie I; Morimoto S; Ito A; Chiba K; Kawazoe Y; Tashiro S; Miyamoto J; Sato S; Yamamoto H; Osaki M; Kawakami A; Abiru N
Trials; 2020 May; 21(1):379. PubMed ID: 32370806
[TBL] [Abstract][Full Text] [Related]
16. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
Lacourcière Y; Neutel JM; Davidai G; Koval S
Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
[TBL] [Abstract][Full Text] [Related]
19. Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S; Nomoto H; Yokoyama H; Suzuki Y; Tsuzuki A; Takahashi K; Miya A; Kameda H; Cho KY; Takeuchi J; Nagai S; Taneda S; Kurihara Y; Nakamura A; Atsumi T;
Diabetes Obes Metab; 2024 Mar; 26(3):961-970. PubMed ID: 38073422
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Shigiyama F; Kumashiro N; Fuchigami A; Hirose T
Cardiovasc Diabetol; 2018 Jun; 17(1):86. PubMed ID: 29895330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
